Multiple Myeloma Clinical Trials in Boston, Massachusetts
51 recruitingBoston, Massachusetts
Showing 1–20 of 51 trials
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Phase 2
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled39 locationsNCT06140524
Recruiting
Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Relapsed/Refractory Multiple Myeloma
AstraZeneca508 enrolled116 locationsNCT07391657
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 2
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC157 enrolled51 locationsNCT07266441
Recruiting
Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Multiple Myeloma
European Myeloma Network B.V.1,594 enrolled212 locationsNCT05243797
Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Hodgkin LymphomaNon-Hodgkin LymphomaHematologic Malignancies+14 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 2
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company230 enrolled52 locationsNCT06297226
Recruiting
Phase 1Phase 2
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.166 enrolled10 locationsNCT07116616
Recruiting
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Smoldering Multiple MyelomaMyelodysplastic SyndromesWaldenstrom Macroglobulinemia+5 more
Dana-Farber Cancer Institute10,000 enrolled7 locationsNCT02269592
Recruiting
Phase 1
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Acute Myeloid LeukemiaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+10 more
Newave Pharmaceutical Inc100 enrolled8 locationsNCT04771572
Recruiting
Not Applicable
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Multiple MyelomaLymphomaLeukemia+2 more
Massachusetts General Hospital90 enrolled1 locationNCT05646576
Recruiting
Phase 2
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Multiple MyelomaMonoclonal Gammopathy of Renal Significance
Memorial Sloan Kettering Cancer Center20 enrolled11 locationsNCT06083922
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Multiple MyelomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute+1 more
Sumitomo Pharma America, Inc.606 enrolled104 locationsNCT04988555
Recruiting
Phase 2
Elranatamab in R/R Multiple Myeloma
Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma
Massachusetts General Hospital32 enrolled3 locationsNCT06138275
Recruiting
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Multiple Myeloma
Boston Medical Center10,000 enrolled1 locationNCT00898235
Recruiting
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
Multiple MyelomaAcute Kidney InjuryLight Chain Nephropathy
Brigham and Women's Hospital450 enrolled1 locationNCT06483139
Recruiting
Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Multiple MyelomaRelapseMultiple Myeloma in Relapse+1 more
Andrew Yee, MD43 enrolled3 locationsNCT04176718
Recruiting
Phase 1Phase 2
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Bristol-Myers Squibb260 enrolled17 locationsNCT05372354
Recruiting
Phase 2
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Multiple MyelomaSmoldering Multiple MyelomaHigh Risk Smoldering Multiple Myeloma
Irene Ghobrial, MD52 enrolled3 locationsNCT05469893